NewsRoom Articles - Page 65 of 154 - PsychedelicNewsWire (PNW)

ThursdayMar 24, 2022 3:42 pm

The Five Most Pivotal Psychedelics Studies So Far

Numerous studies on psychedelics have been conducted since the substances went mainstream a couple of years ago. Since then, a lot has been unearthed about the therapeutic benefits these drugs possess. Here are some important studies on psychedelics that are currently being conducted or are complete. Compass Pathways phase IIb trial Compass Pathways published data on its psychedelic clinical trial, which used psilocybin therapy to manage treatment-resistant depression in 2021. Trial results show that at least 36% of the participants saw a considerable reduction in their symptoms three weeks after the treatment has ended, with almost 30% of these participants…

ThursdayMar 24, 2022 9:15 am

Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Is a Leader in Psychedelic-Based Therapies; Recent Preclinical Research Shows Treatment Effective for MDD

Study shows that substantial antidepressant effects of psilocybin-based treatment, given with supportive psychotherapy, may last at least a year. Psilocybin could lead to significant, durable improvements in depression. Cybin is focused on improving overall mental health through psychedelic-based therapies. Johns Hopkins Medicine researchers have released a report noting that psilocybin treatment for major depression is effective for up to a year for many patients (https://ibn.fm/ZF8jH). That bodes well for Cybin (NYSE American: CYBN) (NEO: CYBN), a leading ethical biopharmaceutical company that is focused on revolutionizing mental health care, including major depressive disorder (“MDD”). “Previous studies by Johns Hopkins Medicine researchers…

WednesdayMar 23, 2022 3:38 pm

Colorado Psychedelics Activists Unite Behind November Ballot Measure

Activists in Colorado have decided to proceed with a single proposal to legalize psilocybin. This proposal, which is one of the quartet of psychedelic reform ballot measures drafted and filed for this year's ballot, will also offer a pathway for the sealing of prior conviction records and establish healing centers where individuals can use psilocybin for therapeutic purposes. The measure, known as Initiative 58, would also allow regulators to decide whether to legalize mescaline, ibogaine and DMT. Veronica Perez and Kevin Matthews, who managed the campaign behind Denver’s historic vote to locally decriminalize psilocybin in 2019, are the brains behind…

TuesdayMar 22, 2022 2:17 pm

Washington State Lawmakers Allocate $200K to Psilocybin Research

Last week, legislators in Washington State advanced a budget measure to the state’s governor. This measure includes a proposal to allocate $200,000 in funding to be used to support the Psilocybin Wellness Workgroup to study the possible legalization of psilocybin services in the state. If the bill is approved by Gov. Jay Inslee, the workgroup will be tasked with compiling a report on psilocybin services opportunities and wellness as stated in the 2023 fiscal year budget proposal. Most of the focus on the psilocybin section will center on analysis and potential improvements that can be made to a Senate measure,…

MondayMar 21, 2022 12:52 pm

Following the Ukraine War on Social Media May Negatively Impact Mental Health

We recently saw Russia invade Ukraine, which prompted millions of Ukrainians to flee their homes as the war intensified. Disturbing videos and photos of the damage done to buildings and people in cities such as Kharkov and Kyiv can be accessed online, even by those thousands of miles away. With many watching the crisis unfold through the standard news sources as well as on social media applications such as Instagram and TikTok, checking for updates isn’t hard to do. However, research has found that coverage of traumatic events on the news can negatively affect the mental health of viewers. Professor…

FridayMar 18, 2022 3:46 pm

Psychedelics Industry Sees Huge Interest from Pharmaceutical Sector Players

Various companies and experts are hailing psychedelics such as MDMA, LSD and psilocybin, as well as mind-altering substances such as ketamine, as the next revolutionary treatment for a number of mental health conditions. The surge in the popularity of psychedelic substances started almost a decade ago, with different research groups at the University of Zurich, Imperial College London, New York University, Johns Hopkins University and the University of California discovering the rapid and lasting effects of using psychedelics, including psilocybin, to treat small groups of individuals with existential distress and treatment-resistant depression. The results from these studies broke the model…

FridayMar 18, 2022 9:15 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Offers a Glimpse into its R&D Pipeline, Patent Strategies, and Clinical Trials at March Investor Conferences

Mydecine participated in this year’s Annual Roth Conference, the Oppenheimer & Co. Annual Healthcare Conference, and will be at the upcoming Maxim Group’s Virtual Growth Conference These conferences represent an opportunity for the company to share its R&D pipeline, patent strategies and ongoing clinical trials Mydecine’s management has optimism for the future, as it taps into the growing psychedelics therapeutics and smoking cessation markets Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) has been at the forefront of developing novel psychedelic and non-psychedelic molecules for medical use. Its research and development efforts have focused on compounds that can enable safer and…

ThursdayMar 17, 2022 1:11 pm

Study Suggests That MDMA Therapy for PTSD May Save Millions in Healthcare Costs

A new study has found that MDMA-assisted therapy may extend and improve the lives of patients suffering from severe and chronic PTSD and also decrease the cost of healthcare. MDMA is a drug known to alter an individual’s mood and perception; it is commonly referred to as molly or ecstasy. Elliot Marseille, the study’s corresponding author, stated that he launched the Global Initiative for Psychedelic Science Economics together with his colleagues from UC Berkeley and UCSF after seeing encouraging results on psychedelic-assisted therapy from different clinical trials. Marseille, who is also the founder of Health Strategies International, explained that the…

ThursdayMar 17, 2022 9:15 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Aiming to Reach Millions of Mental Health Patients with Effective, Affordable Ketamine Treatments

Mental health conditions affect millions of people globally, some of whom are resistant to existing treatments In the early 1990s, Yale researchers discovered that ketamine offered immediate relief to chronically depressed patients, and since then, the scientists have continually investigated the compound’s role in mental health treatment Delic’s subsidiary, Ketamine Wellness Centers, notes that ketamine is now extensively used for multiple treatment-resistant mental conditions, with patient outcomes showing its therapeutic effectiveness Delic hopes to reach millions of people suffering from various mental health conditions who have lost hope of finding effective, affordable treatments The World Health Organization (“WHO”) reports that…

ThursdayMar 17, 2022 9:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) on Leading Edge of Development of Psychedelics as Public Support Grows

More than 60% of American who suffer from mental health conditions want access to psychedelic options Growing number of cities, states looking at decriminalizing use of psychedelic medicine Cybin is working with world-class partners, internationally recognized scientists to create safe, effective therapeutics in the mental-health space The awareness of psychedelics and the potential for treating an array of mental health diseases is growing, as evidenced by a recent survey reporting that 65% of affected Americans want access to psychedelics for potential treatment (https://ibn.fm/jIV2K). Those are numbers that Cybin (NEO: CYBN) (NYSE American: CYBN), a leading ethical biopharmaceutical company, is paying close attention…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000